Table A1.
Strengths and limitations of routinely used thromboprophylaxis guidelines in AF (n = 15)
| n (%) | |
|---|---|
| Strengths of clinical guidelines | |
| Clear recommendations | 9 (60.0%) |
| Detailed recommendations supported by evidence | 6 (40.0%) |
| Easy to follow algorithms | 6 (40.0%) |
| Online availability | 5 (33.3%) |
| Clinical applicability/flexibility | 3 (20.0%) |
| Concise | 3 (20.0%) |
| Most authoritative guideline in Australia | 1 (6.7%) |
| Major limitations of clinical guidelines | |
| I have not noticed any major limitations. | 9 (60.0%) |
| Too long | 3 (20.0%) |
| Difficult to access/not user‐friendly | 2 (13.3%) |
| Disagrees with the PBS criteria | 1 (6.7%) |
| Do not consider patient preferences | 1 (6.7%) |
| Limited clinical flexibility (not patient‐specific) | 1 (6.7%) |
| Unclear recommendations | 1 (6.7%) |
| Difficult to follow algorithms | 1 (6.7%) |
| Helpfulness of clinical guidelines in challenging/uncertain clinical decisions | |
| Very helpful | 3 (20.0%) |
| Helpful | 8 (53.3%) |
| Slightly helpful | 4 (26.7%) |
| Not helpful at all | 0 (0.0%) |
Abbreviations: AF, atrial fibrillation; PBS, Pharmaceutical Benefits Scheme.